Navigation Links
Certain biofuel mandates unlikely to be met by 2022; unless new technologies, policies developed
Date:10/4/2011

ortunities

Key barriers to achieving the renewable fuel mandate are the high cost of producing cellulosic biofuels compared with petroleum-based fuels and uncertainties in future biofuel markets, the report finds. Biofuel production is contingent on subsidies, the nature of the mandate, and similar policies. Although the mandate guarantees a market for the cellulosic biofuels produced, even at costs considerably higher than fossil fuels, uncertainties in enforcement and implementation of the mandated levels affect investors' confidence and discourage investment. To reduce costs of biofuels, the committee suggested carrying out research and development to improve feedstock yield and increasing the conversion yield from biomass to fuels.


'/>"/>

Contact: Jennifer Walsh
news@nas.edu
202-334-2138
National Academy of Sciences
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Era of canopy crane ending; certain research and education activities remain
2. Prenatal exposure to certain pesticides may negatively impact cognitive development in children
3. Uncertain future for Joshua trees projected with climate change
4. Study shows new treatment strategy effective for certain lung cancers
5. Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds
6. Certain parts of the brain activated in people who heard tailored health messages and quit smoking
7. Research shows positive results with high pressure technology for certain dairy products
8. A positive step in the face of uncertainty
9. Apes unwilling to gamble when odds are uncertain
10. Concerns about the safety of certain healthful plant-based antioxidants
11. Father absence linked to earlier puberty among certain girls
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... SHENZHEN, China , 31. Juli 2015 Die ... ) wird von BGI veranstaltet und findet vom ... Shenzhen, China , statt. ... Jubiläum. Seit ihrem Start 2006 ist die ICG ... Bereich „omik" geworden. Sie ist eines der dynamischsten, ...
(Date:7/31/2015)... -- The 10 th International Conference on Genomics (ICG-10, ... 2015, in Shenzhen , China ... th anniversary this year. Since its inauguration in 2006, ... meetings in the ,omics, fields, and is one of the ... ICG-10 focuses on recent breakthroughs and advances in ,omics, research ...
(Date:7/27/2015)... JOSE, Calif. , July 27, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... ® touchscreen solution for its stylish smartwatch. ... for its proven reliability, low power and highly ... a wet finger. Huawei designers also required a ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... international team of researchers led by investigators in the U.S. and ... a common cell cycle that fuels growth in plants, animals and ... of the Earth,s biomass. This discovery, led by a geneticist at ... Nature , leads to a new understanding of how cells grow ...
... at a school beside an informal electronic waste salvage ... lead, cadmium and other health-threatening pollutants over 50 times ... church headquarters and a soccer field are likewise polluted ... metal site, where electronic trash is scavenged for valuable ...
... 29, 2011) A major public symposium at Boston College ... day-long examination of the contributions of the physical and social ... ,Science in the Liberal Arts University Why It ... by BC,s Institute for the Liberal Arts, takes place today ...
Cached Biology News:Research team clarifies mechanics of first new cell cycle to be described in more than 20 years 2Research team clarifies mechanics of first new cell cycle to be described in more than 20 years 3High toxic levels found at school, market neighboring informal e-waste salvage site in Africa 2High toxic levels found at school, market neighboring informal e-waste salvage site in Africa 3High toxic levels found at school, market neighboring informal e-waste salvage site in Africa 4High toxic levels found at school, market neighboring informal e-waste salvage site in Africa 5Science in the liberal arts university 2
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... for the detection and quantification of partially hydrolyzed gluten in foods, has been ... Board adopted the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 ...
(Date:7/30/2015)... USA (PRWEB) , ... July 30, 2015 , ... ... microsystems, has appointed Francois Vieillard as Sales & Marketing Director. , With ... Francois Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against the ... $697 million compared to $701 million in the second ... changes in foreign currency exchange rates decreased sales by ... By business unit, organic sales growth was 6% in ... , Reported diluted EPS was $0.98 compared to ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), ... (MS), today announced that the independent Data Safety Monitoring ... MAESTRO-03 trial of dirucotide in patients with secondary progressive ... the trial continue as per the protocol. , This ...
... Calif., April 14 Zenobia Therapeutics, Inc., the ... the central nervous system, announced successful completion of ... Syntonix Pharmaceuticals, a wholly-owned subsidiary of Biogen Idec ... the agreement, Syntonix gains access to Zenobia,s technology ...
... Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) provides ... 2009 third quarter and nine-month period ended February 28, ... fiscal year 2009 now ending on February, 28. , ... February 28, 2009 in the range of $3,400,000 to ...
Cached Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 3Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 4Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 5
Peptide-affinity Purified Polyclonal Antibody to SMAD7 Peptide with sequence SSCPCWLEVIFNSR, from C Terminus of the protein sequence according to NP_005895....
Purified anti-PXR...
Polyclonal Antibody to PRG3...
Goat polyclonal to MLH3 ( Abpromise for all tested applications). entrezGeneID: 27030 SwissProtID: Q9UHC1...
Biology Products: